Skip to main navigation Skip to search Skip to main content

Effective therapy for acute antibody-mediated rejection with mild chronic changes: Case report and review of the literature

  • Osama Gheith*
  • , Torki Al-Otaibi
  • , Narayanan Nampoory
  • , Medhat Halim
  • , Prasad Nair
  • , Tarek Saied
  • , Salah Al-Waheeb
  • , Ibraheem Muzeirei
  • , Mona Ibraheim
  • *Corresponding author for this work
  • Department of Nephrology
  • Ibn Sina Hospital Safat
  • Immunology Department

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

To reduce the long-term toxicities of immuno - suppressant drugs, corticosteroid-sparing and calcineurin-inhibitor-sparing immunosuppression protocols have become increasingly popular in managing kidney transplant recipients. The most vexing clinical condition caused by antibodies in organ transplants is antibody-mediated rejection. Limitations of the current antibody-mediated rejection therapies include (1) antibody-mediated rejection reversal tends to be gradual rather than prompt, (2) expense, (3) rejection reversal rates below 80%, (4) common appearance of chronic rejection after antibody-mediated rejection treatment, and (5) long-term persistence of donor specific antibodies after therapy. Because these limitations may be due to a lack of effects on mature plasma cells, the effects of bortezomib on mature plasma cells may represent a quantum advance in antihumoral therapy. Our experiences represent the first clinical use of bortezomib as an antihumoral agent in renal allograft recipients in Kuwait. We present 2 cases with resistant-acute antibody-mediated rejection to the standard therapies that were managed successfully with bortezomib.

Original languageEnglish
Pages (from-to)406-409
Number of pages4
JournalExperimental and Clinical Transplantation
Volume10
Issue number4
DOIs
StatePublished - 2012

Keywords

  • Antibody-mediated rejection
  • Bortezomib
  • Renal transplant

Fingerprint

Dive into the research topics of 'Effective therapy for acute antibody-mediated rejection with mild chronic changes: Case report and review of the literature'. Together they form a unique fingerprint.

Cite this